Alnylam Pharma (ALNY) Misses Q3 EPS by 42c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $286.41 +2.99%
EPS Growth %: +409.4%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +409.4%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($2.43), $0.42 worse than the analyst estimate of ($2.01). Revenue for the quarter came in at $2.07 million versus the consensus estimate of $18.23 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- C.H. Robinson acquires DeSpir Logistics for $75 million
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
